Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Guardant Health, Inc.    GH

GUARDANT HEALTH, INC.

(GH)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/21/2021 01/22/2021 01/25/2021 01/26/2021 01/27/2021 Date
162.06(c) 159.92(c) 157.3(c) 149.91(c) 147.39(c) Last
1 009 301 709 528 877 587 1 403 166 1 359 712 Volume
-0.78% -1.32% -1.64% -4.70% -1.68% Change
More quotes
Financials (USD)
Sales 2020 285 M - -
Net income 2020 -218 M - -
Net cash position 2020 1 305 M - -
P/E ratio 2020 -68,4x
Yield 2020 -
Sales 2021 377 M - -
Net income 2021 -169 M - -
Net cash position 2021 1 175 M - -
P/E ratio 2021 -89,2x
Yield 2021 -
Capitalization 14 735 M 14 735 M -
EV / Sales 2020 47,1x
EV / Sales 2021 36,0x
Nbr of Employees 622
Free-Float 92,9%
More Financials
Company
Guardant Health, Inc. is a precision oncology company. The Company is focused on helping conquer cancer through use of its blood tests, data sets and analytics. It provides Guardant Health Oncology Platform. It provides liquid biopsy tests, such as Guardant360 and GuardantOMNI, for advanced stage cancer. Its liquid biopsy tests fuels its programs developing tests for recurrence and early detection, LUNAR-1 and... 
More about the company
Notations Surperformance© of Guardant Health, Inc.
Trading Rating : Investor Rating :
More Ratings
All news about GUARDANT HEALTH, INC.
08:12aGUARDANT HEALTH : Head-to-Head Study Shows Guardant360 Liquid Biopsy Outperforms..
BU
01/19GUARDANT HEALTH : to Partner With Vall d'Hebron Institute of Oncology to Set Up ..
MT
01/18GUARDANT HEALTH : and Vall d'Hebron Institute of Oncology Announce Partnership t..
BU
01/14GUARDANT HEALTH : to Present Data at ASCO Gastrointestinal Cancers Symposium Sho..
BU
01/11GUARDANT HEALTH, INC. : Regulation FD Disclosure, Financial Statements and Exhib..
AQ
01/11GUARDANT HEALTH : Stifel Starts Guardant Health at Buy With $175 Price Target
MT
01/07GUARDANT HEALTH, INC. : Entry into a Material Definitive Agreement (form 8-K)
AQ
2020GUARDANT HEALTH : to Participate in the 39th Annual J.P. Morgan Healthcare Confe..
BU
2020GUARDANT HEALTH : AMEA Wins Frost & Sullivan's Market Leadership Award for Liqui..
AQ
2020Guardant Health Names Michael Bell as CFO
MT
2020GUARDANT HEALTH, INC. : Change in Directors or Principal Officers, Regulation FD..
AQ
2020GUARDANT HEALTH : Names Michael Bell as New Chief Financial Officer
BU
2020GUARDANT HEALTH : SVB Leerink Adjusts Guardant Health's Price Target to $150 Fro..
MT
2020GUARDANT HEALTH : Presents Data at San Antonio Breast Cancer Symposium Demonstra..
BU
2020GUARDANT HEALTH, INC. : Entry into a Material Definitive Agreement, Creation of ..
AQ
More news
News in other languages on GUARDANT HEALTH, INC.
01/19GUARDANT HEALTH : und das Vall d'Hebron Institute of Oncology geben Partnerschaf..
01/19GUARDANT HEALTH : et l'Institut d'oncologie de Vall d'Hebron annoncent un parten..
2019Vision Fund veut garantir un prêt par ses parts dans Uber
More news
Analyst Recommendations on GUARDANT HEALTH, INC.
More recommendations
Chart GUARDANT HEALTH, INC.
Duration : Period :
Guardant Health, Inc. Technical Analysis Chart | GH | US40131M1099 | MarketScreener
Technical analysis trends GUARDANT HEALTH, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 12
Average target price 156,36 $
Last Close Price 149,91 $
Spread / Highest target 26,7%
Spread / Average Target 4,31%
Spread / Lowest Target -44,6%
EPS Revisions
Managers and Directors
NameTitle
Helmy Eltoukhy Chief Executive Officer & Director
AmrAli H. Talasaz Chairman, President & Chief Operations Officer
Michael Bell Chief Financial Officer
Kumud Kalia Chief Information Officer
Darya Chudova Senior Vice President-Technology
Sector and Competitors